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ABSTRACT
Introduction Community- based strategies can extend 
coverage of HIV testing and diagnose HIV at earlier stages 
of infection but can be costly to implement. We evaluated 
the costs and effects of community- led delivery of HIV self- 
testing (HIVST) in Mangochi District, Malawi.
Methods This economic evaluation was based within 
a pragmatic cluster- randomised trial of 30 group 
village heads and their catchment areas comparing 
the community- led HIVST intervention in addition to 
the standard of care (SOC) versus the SOC alone. The 
intervention involved mobilising community health groups 
to lead 7- day HIVST campaigns including distribution of 
HIVST kits. The SOC included facility- based HIV testing 
services. Primary costings estimated economic costs of 
the intervention and SOC from the provider perspective, 
with costs annualised and measured in 2018 US$. A 
postintervention survey captured individual- level data on 
HIV testing events, which were combined with unit costs 
from primary costings, and outcomes. The incremental 
cost per person tested HIV- positive and associated 
uncertainty were estimated.
Results Overall, the community- led HIVST intervention 
costed $138 624 or $5.70 per HIVST kit distributed, 
with test kits and personnel the main contributing 
costs. The SOC costed $263 400 or $4.57 per person 
tested. Individual- level provider costs were higher in the 
community- led HIVST arm than the SOC arm (adjusted 
mean difference $3.77, 95% CI $2.44 to $5.10; p<0.001), 
while the intervention effect on HIV positivity varied based 
on adjustment for previous diagnosis. The incremental cost 
per person tested HIV positive was $324 but increased to 
$1312 and $985 when adjusting for previously diagnosed 
self- testers or self- testers on treatment, respectively. 
Community- led HIVST demonstrated low probability of 
being cost- effective against plausible willingness- to- pay 
values, with HIV positivity a key determinant.
Conclusion Community- led HIVST can provide HIV testing 
at a low additional unit cost. However, adding community- 
led HIVST to the SOC was not likely to be cost- effective, 
especially in contexts with low prevalence of undiagnosed 
HIV.
Trial registration number NCT03541382.
INTRODUCTION
Expanding access to HIV testing services 
(HTS) is important for early diagnosis to 
reduce HIV- related morbidity and mortality 
and prevent HIV transmission.1 In 2018, 
approximately 1.7 million people were newly 
infected with HIV, with 800 000 new cases in 
southern and eastern Africa.2 Almost one- 
fifth of HIV- positive individuals were unaware 
of their HIV status.2 Demand and supply- side 
barriers to conventional facility- based HTS 
have resulted in poorer knowledge of HIV 
status among certain population subgroups 
and hindered achievement of HIV elimina-
tion goals.3 4
Aimed at addressing barriers to access, 
community- based strategies can extend 
coverage of HIV testing and diagnose HIV 
Key questions
What is already known?
 ► Community HIV strategies can extend coverage of 
HIV testing and diagnose HIV at earlier stages of in-
fection. However, community- based strategies can 
be costly to implement, with community- led HIV 
self- testing (HIVST) a promising approach for provid-
ing HIV testing services.
What are the new findings?
 ► Community- led HIVST delivered HIV testing at a low 
additional unit cost.
 ► The incremental cost per person tested HIV posi-
tive was sensitive to variation in prevalence of HIV 
positivity. Therefore, the addition of community- led 
HIVST to the standard of care was not likely to be 
cost- effective in contexts with low prevalence of un-
diagnosed HIV.
What do the new findings imply?
 ► Community- led HIVST may be more cost- effective if 
targeted to settings and populations with more sub-
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at earlier stages of infection but can be costly to imple-
ment.4 5 Meeting and maintaining high awareness of 
HIV status is dependent on identifying sustainable 
approaches for providing HTS beyond health facilities, 
especially with declining global funding for community 
health programmes.6 Moreover, as countries successfully 
scale- up HIV testing and treatment services, costs per new 
HIV diagnoses are increasing.7 To remain cost- effective, 
community- based HIV testing strategies must further 
minimise costs and maximise the proportion diagnosed, 
treated or linked to prevention.7
Community- led approaches involve engaging 
underserved communities in disease prevention and 
management.8 Through context- driven design and 
implementation, community participation in health 
programmes has been shown to improve health outcomes 
at low costs.9–12 HIV self- testing (HIVST), which is recom-
mended as an additional strategy to reach underserved 
populations,13 could be introduced within a communi-
ty- led framework to enable direct provision of HTS by 
communities and improve the coverage, efficiency and 
sustainability of community programmes.8
In this study, we evaluated the costs and effects of 
community- led delivery of HIVST within a pragmatic 
cluster- randomised trial comparing community- led 
HIVST in addition to the standard of care (SOC) versus 
the SOC alone.
METHODS
Trial design, setting and participants
We conducted an economic evaluation of communi-
ty- led delivery of HIVST using individual- level data on 
costs and effects generated from a cluster- randomised 
trial in Mangochi District, Malawi. Clusters, defined as 
group village heads and their catchment areas, were 
identified from communities served by five government 
primary health centres in one of the most HIV- prevalent 
districts in Malawi.14 Thirty clusters were randomised 
1:1 to community- led HIVST in addition to the SOC or 
the SOC alone, which includes facility- based HTS. The 
aim of the trial was to determine whether the commu-
nity- led HIVST intervention increased the proportion 
of the population who tested for HIV, especially among 
subgroups with high undiagnosed HIV, including adoles-
cents, older adults and men. The trial protocol and anal-
ysis are reported separately.15 16
The trial was conducted through the Unitaid/Popula-
tion Services International (PSI) HIV Self- Testing Africa 
Initiative (STAR) (http:// hivstar. lshtm. ac. uk/). The 
study team included PSI Malawi, the Malawi- Liverpool- 
Wellcome Trust Clinical Research Programme and the 
Ministry of Health.
Procedures
The community- led HIVST intervention involved mobi-
lising established community health groups to lead 
the design and implementation of HIVST campaigns. 
Established groups included community health action 
groups, who deliver basic health services with government 
community health workers (CHWs) at group village head 
level, and community volunteers, including village health 
committees, who oversee service provision at village level.
The intervention was delivered in groups of two- to- three 
clusters every 14 days and consisted of three main compo-
nents: participatory workshops, trainings and HIVST 
campaigns. Community health action groups and CHWs 
were invited to a 2- day participatory workshop facilitated 
by the study team. To inform the design of an HIVST 
campaign in their respective areas, participants identi-
fied drivers of HIV, available HIV services and barriers 
to access, and underserved subgroups. Participants then 
determined how the campaign would be implemented, 
including plans for distribution of HIVST kits, support 
for linkage to routine HIV services and demand creation 
for HIVST. Afterwards, community volunteers attended 
2- day trainings on how to support HIVST use, interpre-
tation and linkage to routine HIV services. Volunteers 
were also trained on communicating HIV prevention 
messages, managing social harms, handling and storing 
kits, and collecting data.
Community volunteers then delivered 7- day HIVST 
campaigns under the supervision of community health 
action groups and CHWs. Implementation was based on 
strategies outlined by each cluster during participatory 
workshops. Inputs provided by the study team included 
the OraQuick HIV Self- Test (Orasure Technologies, Thai-
land), communications and instructional materials, data 
collection tools and a nationally standardised gratuity 
of MWK 7000 (US$10) per volunteer. Cluster residents 
aged 15 years and older were eligible to take an HIVST 
kit for themselves and an additional kit for secondary 
distribution.
The SOC, which was available in both study arms, 
included HTS provided by the Ministry of Health. HTS 
is primarily available at facility level through provider- 
initiated testing in outpatient services or client- initiated 
testing, or at community level through periodic outreach 
by health facilities. Lay healthcare workers performed 
HIV testing using finger- prick rapid diagnostic tests based 
on serial testing algorithms using Determine HIV-1/2 
and Unigold HIV-1/2.
Cost measurement
Economic costs of the community- led HIVST interven-
tion and the SOC were estimated from the provider 
perspective using global costing guidelines.17 Costing 
methods are more fully described in online supplemental 
text 1. Intervention costs were collected for the 5- month 
intervention period. Financial data were extracted from 
expenditure records, with each expenditure item allo-
cated to a cost category and activity. Financial costs, which 
contributed to the majority of costs due to vertical imple-
mentation, were then supplemented with economic costs. 
Microcosting involved direct observations and interviews 
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sites, with one site selected per subdistrict. Start- up costs 
included the costs of training and sensitisation and costs 
incurred during the start- up period in the month prior 
to the intervention. Implementation costs included costs 
of capital and recurrent inputs, including building and 
storage, equipment, vehicles, personnel, supplies and 
HIVST kits (unit price of US$2.50). Shared costs between 
HIVST distribution models and sites were allocated 
using the volume of HIVST kits distributed, reported 
time use by staff, mileage from the central office to sites, 
and weighted average of allocation factors. The value of 
resources donated by communities were captured but 
excluded from the analysis due to incomplete data collec-
tion.
Costs for the SOC were retrospectively collected for a 
12- month period. Using an ingredients- based approach, 
resources required to deliver HTS were identified by cost 
category and valued based on their quantity and unit 
price through observations and interviews with facility 
personnel in the five health facilities. Unit prices were 
US$0.98 for Determine and US$1.97 for Unigold. Over-
head costs at the health facility level were allocated using 
the number of patients accessing outpatient services and 
HTS and reported time use by staff.
Start- up and capital costs were annualised using a 3% 
discount rate.17 An annualisation timeframe of 2 years was 
assumed for start- up costs, while the useful life for capital 
costs was dependent on input type. Wastage assumptions 
also varied by input type. Local costs were converted to 
2018 US dollars using the median exchange rate over the 
analysis period.18 Overall and site- level unit costs for the 
community- led HIVST intervention and the SOC were 
estimated, with programme and facility registers respec-
tively providing the number of HIVST kits distributed and 
the number of persons tested for the costing periods. The 
number of persons self- tested was obtained by adjusting 
the number of kits distributed with the proportion of kit 
usage reported from the postintervention survey for the 
outcome measurement.
Activity and site- specific unit costs were then combined 
with frequency of HIV testing and self- testing events 
in the last 12 months reported in the postintervention 
survey, with individual- level provider costs estimated for 
each survey participant.
Outcome measurement
For the economic evaluation, we measured the effect of 
the community- led HIVST intervention on the propor-
tion tested HIV positive, defined as individuals who 
self- reported a positive HIV test in the last 12 months 
through the postintervention survey. To measure new 
diagnoses, we alternatively defined the proportion 
tested HIV positive as: (1) testing positive through the 
SOC or newly self- testing positive and (ii) testing posi-
tive through the SOC or self- testing positive and not 
on antiretroviral therapy (ART). HIV testing in the last 
12 months was also included as an outcome of interest. 
Outcomes were captured over a 12- month period, since 
community- led HIVST was designed to be delivered as 
an annual intervention to a high HIV- prevalence popula-
tion who might benefit from recurrent testing. Of note, 
data on previous diagnosis were only collected for indi-
viduals who self- tested and not for individuals who tested 
through standard HTS.19 We also did not account for 
confirmatory testing following HIVST .
Outcomes were measured through a postinterven-
tion survey administered 8–12 weeks after the start of 
the intervention in the community- led HIVST arm or 
corresponding dates in the SOC arm. Cluster residents 
were sampled to form the evaluation population. In each 
cluster, villages with at least 500 residents and located 
near the group head village were randomly selected for 
the survey. Households were then recruited in a clockwise 
spiral starting from a common location across selected 
villages, aiming to include at least 250 participants per 
cluster based on sample size calculations for the trial.15 
Residents aged 15 years and older were eligible to partic-
ipate in the survey, with written informed consent or 
assent obtained. Participants provided information on 
sociodemographic background and prior experience 
with HIV testing and treatment.
Statistical analysis
Incremental costs and effects were estimated using 
individual- level data from the postintervention survey. 
Analysis used intention- to- treat and cluster- level methods 
appropriate for cluster- randomised trials with a small 
number of clusters.20 To estimate the mean difference 
(MD) in costs, we used linear regression to adjust for sex, 
age group and imbalance between arms at the individual 
level. Covariate- adjusted residuals were then summed for 
each cluster and compared by arm using a t- test. Simi-
larly, risk differences (RDs) for the proportion tested 
for HIV and tested HIV- positive were estimated using a 
cluster- level analysis, with logistic regression used at the 
individual level to obtain covariate- adjusted summary 
values.
The incremental cost per person tested and tested HIV 
positive were calculated as the ratio of adjusted incre-
mental costs and adjusted incremental effects. Uncer-
tainty was estimated using two- stage non- parametric 
bootstrap, whereby clusters were sampled in the first 
stage and individuals within clusters were sampled in the 
second stage, both with replacement.21 22 A shrinkage 
correction was applied.21 22 Incremental costs and incre-
mental effects were calculated across 1000 bootstrap 
replicates and plotted on cost- effectiveness planes.23 CIs 
were estimated using bias- corrected percentiles.23 Cost- 
effectiveness acceptability curves were also generated 
from bootstrap replicates to illustrate probabilities for 
a range of willingness- to- pay values. Subgroup analyses 
were conducted to understand differences in individual- 
level costs and effects by sex. Statistical analysis used Stata 
V.14.0.
We compared the incremental cost per person tested 






















ealth: first published as 10.1136/bm




4 Indravudh PP, et al. BMJ Global Health 2021;6:e004593. doi:10.1136/bmjgh-2020-004593
BMJ Global Health
across alternative outcome definitions. The threshold is 
based on a simulation study in Southern Africa, which 
showed that additional testing beyond the SOC was 
considered cost- effective if the cost per new diagnosis 
was below a threshold of 2018 US$315 and therefore 
strongly associated with the cost per disability- adjusted 
life year (DALY) averted below a threshold of 2018 
US$500.7 The threshold represents opportunity costs of 
reallocating resources within an HIV programme from 
other HIV interventions to HIV testing and relevant to 
national programmes dependent on overseas funding.7 
We aimed to improve comparability of our outcome to 
the threshold by adjusting for previous diagnosis among 
self- testers.
Sensitivity and scenario analysis
One- way deterministic sensitivity and scenario analysis 
assessed the impact of varying parameters on the mean 
cost per HIVST kit distributed and the incremental 
cost per person tested HIV positive. In sensitivity anal-
ysis, we varied cost assumptions, including the discount 
rate (none, 16%) and exchange rate (minimum, 
maximum).18 In scenario analysis, we varied inputs that 
were considered to be important cost determinants, 
including the price of HIVST kits from $0.98 (price of 
HIV RDTs) to $3.40 (unsubsidised price of HIVST kits).24 
Furthermore, we modelled real- world scenarios for 
routine implementation under the Ministry of Health by 
varying personnel costs (±10%), start- up costs (±10%), 
lifespan of start- up costs (1 year, 5 years) and number of 
kits distributed (±10%). Parameters were selected based 
on scenarios evaluated in earlier STAR studies in antic-
ipation of scale- up.24 We also estimated best and worst 
case scenarios for routine implementation by adjusting 
parameters that produced the lowest and highest values. 
Lastly, in addition to assessing alternative outcome defini-
tions for HIV positivity, we assessed the impact of uncer-
tainty using 95% CIs for the effect estimate.
RESULTS
The community- led HIVST intervention was delivered in 
15 clusters between 5 October 2018 to 17 January 2019. 
HIVST campaigns were implemented in each cluster, 
with 157 community health action group members and 
190 community volunteers distributing 24 316 HIVST 
kits. The postintervention survey included 90.2% 
(3960/4388) and 89.2% (3920/4394) of listed residents 
in the community- led HIVST and SOC arms, respectively 
(online supplementary figure 1). Across arms, response 
rates were lower among men (83.5%, 3072/3677) 
compared with women (94.2%, 4808/5105). Participant 
characteristics are summarised in online supplemental 
table 1, with differences between arms observed for 
literacy, religion, ethnicity and self- reported health status.
Costs
The total provider cost of the community- led HIVST 
intervention was $138 624, which includes costs for the 
5- month start- up and implementation period (table 1). 
The proportion of start- up and capital costs were respec-
tively 10.3% ($14 308) and 9.4% ($13 023). Recurrent 
costs accounted for 80.3% ($111 293) of the total cost, with 
the main contributing inputs including test kits (46.0%) 
followed by personnel (25.3%) and vehicle operation 
and maintenance (4.2%). The mean cost per HIVST kit 
distributed was $5.70. Mean costs varied by cluster from 
$4.45 to $8.49, with lower costs achieved in clusters with 
higher volumes of kits distributed (online supplemental 
figure 2). The mean cost per person self- tested was $5.73, 
which was estimated based on self- reported kit usage 
among survey participants who collected kits (99.6%, 
3128/3142).
From January to December 2018, the total provider cost 
of the SOC was $263 400 (table 1). Of total costs, capital 
costs were 3.0% ($7887), while recurrent costs were 
97.0% ($255 513). In contrast with the community- led 
HIVST intervention, personnel (48.1%) contributed the 
largest proportion to costs followed by test kits (24.6%) 
and supplies (23.5%). The mean cost per person tested 
was $4.57, ranging from $2.90 to $6.41 by health facility.
Based on the frequency of HIV testing and self- testing 
events reported in the postintervention survey, partic-
ipants in the community- led HIVST arm had a mean 
number of 1.66 tests in the last 12 months (online 
supplemental figure 3), providing a mean provider cost 
per person of $9.06 (table 2). In the SOC arm, the mean 
number of annual tests was 1.17, with a mean provider 
cost per person of $5.52. The adjusted MD was $3.77 
(95% CI $2.44 to $5.10; p<0.001). Among men, the mean 
cost per person was $8.04 and $4.68 in the community- led 
HIVST and SOC arms, respectively. Mean costs were 
higher for women than men in both the community- led 
HIVST ($9.74) and SOC ($6.04) arms, reflecting higher 
frequency of testing among women. The MD in costs 
were similar among men (adjusted MD 3.57, 95% CI 2.33 
to 4.81; p<0.001) and women (adjusted MD 3.91, 95% CI 
2.49 to 5.32; p<0.001; p value for interaction; p=0.25).
HIV testing
HIV testing in the last 12 months was higher in the commu-
nity- led HIVST arm (84.9%, 3363/3960) compared with 
the SOC arm (65.7%, 2574/3920), with adjusted RD of 
19.5% (95% CI 15.0% to 24.0%; online supplementary 
table 2). The intervention effect was greater among men 
(adjusted RD 23.1%, 95% CI 17.8% to 28.4%; p<0.001) 
than women (adjusted RD 17.2%, 95% CI 12.7% to 
21.8%; p<0.001; p value for interaction=0.002). The 
incremental cost per person tested was $19.35 and lower 
for men ($15.44) than women ($22.67).
HIV positivity
HIV positivity was also higher in the community- led 
HIVST arm (2.6%, 104/3960) than the SOC arm (1.7%, 
67/3920; adjusted RD 1.2%, 95% CI 0.3% to 2.0%; 
p=0.008), with more pronounced differences among 
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p=0.005) than men (adjusted RD 0.5%, 95% CI −0.5% to 
1.5%; p=0.29; p value for interaction=0.06; table 2).
However, differences between arms were not observed 
when the outcome definition excluded previously diag-
nosed self- testers (adjusted RD 0.3%, 95% CI −0.4% to 
1.0%; p=0.42) or self- testers on treatment (adjusted RD 
0.4%, 95% CI −0.3% to 1.1%; p=0.27).
The incremental cost per person tested HIV posi-
tive was $324, and higher for men ($716) compared 
with women ($246) due to lower HIV positivity (online 
supplemental figure 4). The incremental cost per 
person tested positive was $1312 and $985 when previ-
ously diagnosed self- testers or self- testers on treatment 
were excluded. Bias- corrected confidence intervals are 
presented with cost- effectiveness planes in figure 1. The 
joint distribution of the difference in costs and difference 
in the proportion tested positive fell in the upper left and 
right quadrants of the cost- effectiveness plane, meaning 
incurred costs could potentially result in zero or negative 
benefits.
Cost- effectiveness acceptability curves are illustrated in 
figure 2. With respect to a threshold of $315 per positive 
test, cost- effectiveness probabilities varied depending on 
the outcome definition: 45.0% for testing HIV positive, 
30.2% when excluding previously diagnosed self- testers 
and 21.2% when excluding self- testers on treatment.
Sensitivity and scenario analysis
One- way sensitivity and scenario analysis for the mean 
cost per HIVST kit distributed and the incremental cost 
per person tested HIV- positive are presented in figure 3. 
Varying the price of the HIVST kit from $0.98 to $3.40 
led to the largest changes in average costs, from $4.09 to 
$6.70. Best and worst case scenarios for routine practice, 
which varied personnel costs, start- up costs, lifespan of 
start- up costs and the volume of kits, yielded average costs 
Table 1 Total and average unit costs of the community- led HIV self- testing (HIVST) intervention and standard of care (SOC)
Community- led HIVST intervention SOC
Costs Col. % Costs Col. %
Start- up costs $14 308 10.3
  Training $3843 2.8 – –
  Sensitisation $891 0.6 – –
  Start- up other $9573 6.9 – –
Capital costs $13 023 9.4 $7887 3.0
  Building and storage $4907 3.5 $2154 0.8
  Equipment $778 0.6 $1722 0.7
  Vehicles $7338 5.3 $4012 1.5
Recurrent costs $111 293 80.3 $255 513 97.0
  Personnel and per diems $35 111 25.3 $126 805 48.1
  Supplies $1931 1.4 $61 803 23.5
  Test kits $63 830 46.0 $64 802 24.6
  Vehicle operation, maintenance 
and transportation
$5807 4.2 $43 0.0
  Building operation and 
maintenance
$502 0.4 $689 0.3
  Recurrent training – – $1081 0.4
  Waste management – – $290 0.1
  Other recurrent $4113 3.0 – –
Total costs $138 624 $263 400
Number of HIVST kits distributed 24 316 NA
Number of persons tested* 24 219 57 695
Mean cost per HIVST kit 
distributed
$5.70 NA
Mean cost per person tested $5.73 $4.57
Costs in 2018 US$. Costs were collected from September 2018 to January 2019 for the community- led HIVST intervention and from January 
2018 to December 2018 for the SOC.
*Number of persons tested for community- led HIVST was estimated based on the number of HIVST kits distributed and self- reported usage 
of HIVST kits from the postintervention survey (99.6%, 3128/3142).
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ranging from $3.57 to $7.56. Results remained robust to 
variations in sensitivity analysis.
Uncertainty associated with HIV positivity led to the 
largest changes in the incremental cost per person tested 
positive, ranging from $184 to $1141 based on 95% CIs 
for the effect estimate. In best and worst case scenarios 
modelling routine implementation and uncertainty 
in the effect estimate, the incremental cost per person 
tested positive varied from $105 to $1614.
DISCUSSION
We conducted an economic evaluation within a cluster- 
randomised trial of community- led delivery of 7- day 
HIVST campaigns in Malawi. The community- led HIVST 
intervention showed low average cost of $5.70 per 
HIVST kit distributed, with test kits and personnel the 
main contributing costs. Individual- level provider costs 
were higher in the community- led HIVST arm than the 
SOC arm, demonstrating low substitution due to HIVST 
uptake among recently tested individuals. The interven-
tion effect on HIV positivity varied based on adjustment 
for previous diagnosis. The incremental cost per person 
tested HIV positive was $324 but increased to $1312 and 
$985 when adjusting for previously diagnosed self- testers 
or self- testers on treatment, respectively. The addition 
of community- led HIVST to the SOC demonstrated low 
probability of being cost- effective, with HIV positivity a 
key determinant. Despite providing HIV testing at a low 
additional unit cost, community- led HIVST was not likely 
to be a cost- effective strategy, especially in contexts with 
low prevalence of undiagnosed HIV.
Universal HIV testing and treatment can be used to 
support reductions in HIV incidence in the general popu-
lation,1 but financial sustainability remains a limiting 
factor. Our cost analysis showed a mean cost of $5.70 per 
kit distributed through the community- led HIVST inter-
vention and $4.57 per person tested through the SOC. 
The largest contributors to intervention costs were test 
kits, personnel, and vehicle operation and maintenance. 
SOC costs were driven by personnel followed by test kits 
and supplies. Differences in resource use reflect the 
higher price of HIVST kits but lower cost of personnel 
from campaign- style implementation by community 
volunteers. The cost of supplies was also higher in the 
SOC due to recurrent use of medical supplies along-
side provision of HIV RDTs. The average cost for HIVST 
implementation reported in this study is lower than costs 
previously reported for door- to- door distribution of kits 
in Malawi, both in rural (2017 US$8.15) and urban (2014 
US$8.78) settings.24 25 Lower costs are likely influenced by 
the high volume of kits delivered within a short period of 
time in addition to pragmatic implementation through 
Table 2 Incremental costs and effects of community- led HIV self- testing (HIVST)
Community- led 
HIVST arm
Mean or % (n/N)
SOC arm
Mean or n/N 
(%)
Unadjusted mean or 
risk difference (95% CI) 
p value
Adjusted mean 
or risk difference 
(95% CI) * p value
Overall
  Provider costs (2018 US$) 9.06 5.52 3.66 (2.31 to 5.01)
<0.001
3.77 (2.44 to 5.10)
<0.001




1.0% (0.1% to 1.8%)
0.03
1.2% (0.3% to 2.0%)
0.008






0.1% (−0.6 to 0.9%)
0.68
0.3% (−0.4 to 1.0%)
0.42






0.2% (−0.4 to 0.9%)
0.48
0.4% (−0.3 to 1.1%)
0.27
Men§
  Provider costs (2018 US$) 8.04 4.68 3.61 (2.36 to 4.86)
<0.001
3.57 (2.33 to 4.81)
<0.001




0.4% (−0.5 to 1.4%)
0.34
0.5% (−0.5 to 1.5%)
0.29
  Women§
  Provider costs (2018 US$) 9.74 6.04 3.74 (2.25 to 5.23)
<0.001
3.91 (2.49 to 5.32)
<0.001




1.4% (0.3% to 2.5%)
0.02
1.6% (0.5% to 2.6%)
0.005
*Analysis adjusted for sex, age group, literacy, religion, ethnicity and health status. Subgroup analysis adjusts for the same covariates except 
for sex.
†Defined as testing positive through the SOC or newly self- testing positive.
‡Defined as testing positive through the SOC or self- testing positive and not on ART.
§P value for interaction by sex. Provider costs: p=0.25. Tested HIV positive: p=0.06.
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established community health groups, who are routinely 
activated to support basic health service provision.
Our findings highlight potential areas for cost reduc-
tions under scenarios modelling routine implementa-
tion by the Ministry of Health. Personnel salaries and 
per diems contributed substantially to costs and could 
be further reduced under routine practice. Packaging 
HIVST with other health interventions could also reduce 
the ratio of fixed costs, including personnel, to variable 
costs through economies of scope. Recurrent imple-
mentation could produce efficiency gains as community 
health groups become more familiar with HIVST and 
start- up costs are spread over a longer period of time. 
Minimising retesting among recently tested individuals 
or reducing the price of HIVST kits could additionally 
lower costs, with HIVST kits accounting for the majority 
of costs. Furthermore, community- led HIVST is likely to 
realise greater economies of scale as unit costs decrease 
with increasing volume of kits distributed.
A community- led approach has often been promoted 
as a mechanism to include context- specific knowledge 
and resources in health programmes.8 Implementation 
through community- driven systems could lower costs 
and expand the pool of available resources for service 
provision.8 Earlier studies have shown that communi-
ty- led approaches can be less costly than vertically deliv-
ered strategies.26 However, there is a risk of shifting 
economic costs down to resource- constrained commu-
nities. In a multicountry study, community- led multidis-
ease campaigns were less costly than the SOC, but higher 
median opportunity costs were reported by community 
volunteers.26 In our analysis, costs incurred by communi-
ties were not captured due to incomplete data collection, 
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Figure 1 Cost- effectiveness plane for community- led HIV 
self- testing. Cost- effectiveness plane of adding community- 
led HIVST to the standard of care. The incremental cost 
per person tested HIV positive for alternative outcome 
definitions are illustrated. Each point represents the adjusted 
mean difference in cost (incremental cost) and adjusted risk 
difference in the proportion tested HIV positive (incremental 
effect) for one bootstrap replicate. The dark blue circle 
indicates the incremental cost per person tested positive 
and the dark blue line indicates the bootstrap confidence 
intervals using the bias- corrected percentile method. LL, 
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Figure 2 Cost- effectiveness acceptability curves for 
community- led HIVST by scenario. Cost- effectiveness 
acceptability curves of adding community- led HIVST to 
the standard of care. Cost- effectiveness probabilities for 
the incremental cost per person tested HIV positive are 
plotted for alternative outcome definitions across a range of 
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were relatively nominal and included donated building 
space, equipment and transportation. Opportunity costs 
were also captured through gratuity received by commu-
nity volunteers.
Accounting for retesting among previously diagnosed 
self- testers or self- testers on treatment yielded an incre-
mental cost per person tested HIV positive of $1312 and 
$985, respectively. Community volunteers were trained 
to advise against self- testing on ART to avoid false nega-
tive results. However, volunteers did not discourage self- 
testing among recently tested individuals or individuals 
known to be HIV positive but not on treatment. High 
prevalence of retesting among known HIV- positive indi-
viduals has previously been reported for both facility- based 
and community- based services, with retesting moti-
vated by loss to treatment follow- up.27 In Malawi, desire 
to monitor sero- reversion was reported by female sex 
workers, while opportunity for HIV status disclosure was 
described among couples.28 29 Furthermore, we reported 
an increase in the proportion of testing at an additional 
mean cost of $19.35 per person tested, reflecting low 
substitution due to HIVST uptake among recently tested 
individuals. Reasons that have been reported for retesting 
among HIV- negative individuals included to monitor HIV 
status, respond to HIV risk exposure or facilitate partner 
testing.28 30 Pressure to self- test could also lead to unneces-
sary retesting but was reported to be limited in the main 
trial.16 Targeting of subgroups currently underserved by 
facility- based HTS could improve efficiency, with vari-
able costs associated with HIVST kits higher than fixed 
costs. Equally, targeted distribution could heighten stigma 
around HIV testing and reduce uptake among priority 
subgroups. Under such conditions, wider implementa-
tion might be required to identify undiagnosed people 
living with HIV despite losses in efficiency.
Adding community- led HIVST to the SOC had 
21%–45% probability of being cost- effective at a 
threshold of $315 per positive test. We used HIV positivity 
as an outcome but did not distinguish between newly and 
previously identified people living with HIV. We aimed to 
improve comparability with the threshold, which is based 
on the cost per new diagnosis, by adjusting for previ-
ously diagnosed self- testers or self- testers on treatment. 
However, we did not collect data on previous diagnosis 
among individuals who tested through standard HTS 
and may have underestimated known HIV- positive status 
in the SOC arm.19 We also did not account for confir-
matory testing following HIVST and may have overesti-
mated HIV diagnosis in the community- led HIVST arm. 
Furthermore, we used a willingness- to- pay threshold 
recommended for decision making within HIV testing 
programmes, with thresholds as low as $150 per new diag-
nosis suggested when considering resource allocation 
across healthcare services.7
$3.00 $4.00 $5.00 $5.70 $6.00 $7.00 $8.00
Mean cost per HIVST kit distributed
Exchange rate, 2018 US$ to Malawi kwacha (min, max)
Start-up costs for community-led HIVST (-10%, +10%)
Discount rate (0%, 16%)
Personnel costs for community-led HIVST (-10%, +10%)
Lifespan of start-up for community-led HIVST (5, 1)
Number of HIVST kits distributed (-10%, +10%)
Price of OraQuick HIV Self-Test ($0.98, $3.40)
Real-world scenario (best, worst)
Low High
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Incremental cost per person tested HIV-positive
Exchange rate, 2018 US$ to Malawi kwacha (min, max)
Discount rate (0%, 16%)
Start-up costs for community-led HIVST (-10%, +10%)
Personnel costs for community-led HIVST (-10%, +10%)
Number of HIVST kits distributed (-10%, +10%)
Lifespan of start-up for community-led HIVST (5, 1)
Price of OraQuick HIV Self-Test ($0.98, $3.40)
Incremental percentage of persons tested positive (UL, LL)
Real-world scenario (best, worst)
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Figure 3 Tornado diagram of one- way deterministic sensitivity and scenario analysis. Tornado diagram illustrating changes 
in the mean cost per HIVST kit distributed and incremental cost per person tested HIV positive based on variations to inputs. 
Light blue bars represent changes at minimum input values, while dark blue bars represent changes at maximum input values. 
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Cost- effectiveness of community- based HIV testing 
is dependent on minimising implementation costs and 
maximising uptake among populations with high prev-
alence of undiagnosed HIV.31 32 Using a community- led 
approach, we aimed to lessen costs through pragmatic 
and short- term implementation and better outcomes 
through community participation and implementation 
in a high- prevalence district. Mobilising community 
health groups beyond an annual period may improve 
probability of cost- effectiveness, given the low impact on 
HIV positivity reported in this study. Districts with more 
substantial prevalence of undiagnosed HIV should also 
be targeted, though diminishing returns to HIV testing 
will continue to influence cost- effectiveness as countries 
near global HIV targets. Additional health benefits could 
also potentially be gained by delivering HIVST within a 
broader package of multidisease interventions at commu-
nity level.
The main strength of our study is the use of a cluster- 
randomised trial as an instrument for economic evalua-
tion, with our analysis based on individual- level data for 
costs and effects. Individual- level costs were estimated 
using the frequency of HIV testing and self- testing events, 
providing insights into retesting behaviours and potential 
opportunities for efficiency gains. In our analysis, we also 
accounted for the clustered design, correlation between 
costs and effects, and covariate adjustment. Furthermore, 
we present findings from a pragmatic intervention imple-
mented through established community health groups. 
The intervention was aimed at replicating real- world 
implementation, underpinning the generalisability of 
our costs to similar settings in sub- Saharan Africa with 
community health groups. However, our findings on 
cost- effectiveness were highly sensitive to variations in 
HIV positivity.
The study, however, has limitations. First, costs of 
the community- led HIVST intervention were collected 
from the perspective of a non- governmental organisa-
tion rather than the health system. However, we aimed 
to replicate scenarios for routine implementation by 
varying start- up and personnel costs and the volume of 
kits distributed. We also did not account for costs incurred 
by communities and patients, though this was expected 
to be very low.25 Second, individual- level costs and effects 
are based on self- report and subject to recall or social 
desirability bias, with potential for over- reporting in the 
community- led HIVST arm following exposure to the 
intervention. Third, trial- based economic evaluations 
have limitations, with the time horizon for evaluating 
costs and effects limited to the trial period. Fourth, our 
outcome was restricted to HIV positivity. We aimed to 
adjust our outcome for known HIV- positive individuals 
to improve comparability with the willingness- to- pay 
threshold based on the cost per new diagnosis. However, 
we were unable to account for previous diagnosis 
under standard HTS or confirmatory testing following 
HIVST. We also did not evaluate treatment or preven-
tion outcomes or generic health endpoints. Finally, we 
did not consider non- health benefits associated with 
community- led programmes.33
CONCLUSION
Community- led delivery of 7- day HIVST campaigns 
provided HIV testing at a low additional unit cost. 
However, adding community- led HIVST to the SOC was 
not likely to be cost- effective, especially in contexts with 
low prevalence of undiagnosed HIV. To maximise the 
value of community- led HIVST, we recommend targeted 
delivery to settings and populations with more substantial 
prevalence of undiagnosed HIV.
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